May 21, 2021. Student nurse Dario Gomez, center, disinfects a chair after administering the Pfizer COVID-19 vaccine to a patient at Providence Edwards Lifesciences vaccination site in Santa Ana, Calif. U.S.AP Photo/Jae C. Hong

The coronavirus is a rapidly developing news story, so some of the content in this article might be out of date. Check out our most recent coverage of the coronavirus crisis, and subscribe to the Mother Jones Daily newsletter.

More good vaccine news is here: According to new data, the Pfizer coronavirus vaccine has “high levels of effectiveness” against the highly transmissible variant found in India. The data, from Public Health England, an agency in the UK department of health, studied Pfizer’s efficacy after two doses and found it was 88 percent effective in preventing symptomatic cases of the B.1.617.2 variant. 

Researchers found that the Pfizer shot is also highly effective against B.117, the variant first found in the UK, preventing 93 percent of symptomatic cases. And as with other variants, “even higher levels of effectiveness are expected against hospitalisation and death” after the second dose, according to the UK officials. Researchers also studied the effectiveness of the AstraZeneca vaccine, which has been used widely in the UK but has not yet been approved in the US; data shows it was was 60 percent effective against the B.1.617.2 variant, and 66 percent effective against B.117.

While the number of coronavirus cases and deaths have dropped in the United States as more people get vaccinated, the pandemic is not over yet. Other countries across the world are seeing the opposite trajectory, with more deaths and more confirmed cases. As Saturday’s announcement confirmed the efficacy of the vaccines against new variants, we passed the 165 million mark of coronavirus cases worldwide. Data from Johns Hopkins University shows that globally almost 3.5 million people have died from the virus. 

OUR DEADLINE MATH PROBLEM

It’s risky, but also unavoidable: A full one-third of the dollars that we need to pay for the journalism you rely on has to get raised in December. A good December means our newsroom is fully staffed, well-resourced, and on the beat. A bad one portends budget trouble and hard choices.

The December 31 deadline is drawing nearer, and if we’re going to have any chance of making our goal, we need those of you who’ve never pitched in before to join the ranks of MoJo donors.

We simply can’t afford to come up short. There is no cushion in our razor-thin budget—no backup, no alternative sources of revenue to balance our books. Corporations and powerful people with deep pockets will never sustain the fierce journalism we do. That’s why we need you to show up for us right now.

payment methods

OUR DEADLINE MATH PROBLEM

It’s risky, but also unavoidable: A full one-third of the dollars that we need to pay for the journalism you rely on has to get raised in December. A good December means our newsroom is fully staffed, well-resourced, and on the beat. A bad one portends budget trouble and hard choices.

The December 31 deadline is drawing nearer, and if we’re going to have any chance of making our goal, we need those of you who’ve never pitched in before to join the ranks of MoJo donors.

We simply can’t afford to come up short. There is no cushion in our razor-thin budget—no backup, no alternative sources of revenue to balance our books. Corporations and powerful people with deep pockets will never sustain the fierce journalism we do. That’s why we need you to show up for us right now.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate